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Abstract
Cannabinergic and vanilloidergic signaling are mechanisms of interest for the treatment of
anxiety symptoms due to the anxiolytic properties of cannabinoid type 1 receptor (CB1R)
activation and transient potential vanilloid type 1 channel (TRPV1) inhibition. Arachidonoyl
serotonin (AA-5-HT), a dual fatty acid amide hydrolase and TRPV1 inhibitor provides an
efficient means of modulating these systems. We therefore examined the effects of AA-5-HT on
anxiety- and fear-like behaviors in male low (C57BL/6J; [B6]) and high (BALB/cJ; [BCJ])
anxiety mice in light/dark box (LDB), open-field (OF), and fear extinction (FE) paradigms. AA5-HT (1 mg/kg) administration did not affect anxiety-related behaviors in the LDB or OF in B6
mice. However, AA-5-HT treatment attenuated generalized fear compared to vehicl treated B6s.
AA-5-HT administration increased rearing and locomotion in the LDB in BCJ mice but did not
affect fear-related behaviors. In vivo fixed potential amperometry was used to determine
whether AA-5-HT administration modulates phasic dopamine release in the basolateral
amygdala (BLA) and nucleus accumbens (NAc) of mice. AA-5-HT treatment inhibited phasic
dopamine release in the BLA of BCJs and the NAc of B6s. Our results suggest that contextual
factors interact with basal anxiety levels to modulate the effects of cannabinergic signaling on
anxiety-related behaviors. We also provide evidence of cannabinergic and dopaminergic
interactions in the BLA which could affect anxiety and fear. The lack of elevated subsecond
dopamine release observed in the NAc following systemic AA-5-HT administration suggests that
the drug may not produce rewarding effect by enhancing peak dopamine release in this region.
Ultimately, our findings imply that the utility of AA-5-HT as an anxiolytic drug may limited by
individual differences in contextual factors and basal anxiety symptoms in humans.
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Introduction
Fundamentally, anxiety is an anticipatory process that allows human and non-human
animals to predict aversive events based on past experiences (Barlow, 2000; Brosschot, Verkuil,
& Thayer, 2016; Grupe & Nitschke, 2013). Such prediction enhances the ability to adapt to
threatening situations should they transpire. Therefore, anxiety-related behaviors are not, in and
of themselves, problematic. These behaviors become maladaptive, however, when they are
displayed at an excessive degree relative to a stressor’s objective threat level, namely when the
stressor is uncertain in nature (Brosschot, Verkuil, & Thayer, 2016; Grupe & Nitschke, 2013).
Unfortunately, misperceptions regarding stressor-threat relationships and low tolerance for
uncertainty are commonplace.
Anxiety disorders are costly, prevalent health issues in the U.S. The adult population
pays nearly $33 billion in medical costs for anxiety-symptom treatment every year (Shrineshan
et al., 2013). Approximately 18% of the U.S. adult population experiences anxiety symptoms
annually; furthermore, about 22% of those suffering from such symptoms are considered severe
cases (Kessler, Chiu, Demler, & Walters, 2005). These severe symptoms can negatively impact
a person’s ability to maintain positive relationships with others and function at work, school, and
in everyday life (American Psychological Association [APA], 2013). Given that these issues are
persistent, there is a need to refine our methods of treating anxiety symptoms.
The benefits of conventional anxiolytics are limited. For example, people using chronic
benzodiazepine treatments are at risk for developing benzodiazepine dependence (Farach et al.,
2012). Antidepressants, which have anxiolytic properties, have been associated with notable
non-response rates (e.g., 44%), and some people have experienced increased anxiety symptom
severity within the first 2 weeks of antidepressant treatment (Gollan et al., 2012; Montogmery,
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Sheehan, Meoni, Haudiquet, & Hackett, 2002). Considering the limitations of current
anxiolytics, it is evident that new pharmacological treatments for anxiety symptoms are needed.
A promising target for the development of these treatments is the cannabinergic system.
Cannabinergic Signaling in Anxiety
The two primary cannabinoid (CB) receptors that have been identified are the
cannabinoid type 1 receptors (CB1Rs) which are localized in the central nervous system (CNS)
on presynaptic neurons and the cannabinoid type 2 receptors (CB2Rs) which are mainly found in
the peripheral nervous system (PNS; Howlett et al., 2002; Kano, Ohno-Shosaku, Hashimotodani,
Uchigashima, & Watanabe, 2009; Marinelli et al., 2007). High densities of CB1Rs are present in
regions of the brain that are associated with regulating emotional processing and behaviors (e.g.,
amygdala, prefrontal cortex, periaqueductal grey, and hippocampus), suggesting the involvement
of this system in anxiety-related behaviors (Rubino et al., 2008). These receptors bind the
endocannabinoids (eCBs) N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2AG) which are synthesized in response to postsynaptic neuron depolarization and then rapidly
released (Kano et al., 2009; Howlett et al., 2002). eCBs operate via retrograde inhibitory
signaling in which they migrate backwards across the synapse and bind to presynaptic CB1/2Rs,
ultimately inhibiting neurotransmitter release (Howlett et al., 2002; Patel & Hillard, 2006). eCB
activity in the synapse is terminated through degradation of 2-AG and AEA by
monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase, respectively (FAAH; Kano et
al., 2009). In summation, pharmacological manipulation of CB1R signaling, eCB transport,
and/or eCB enzyme functioning can be used to modulate anxiety-like responses to anxiogenic
stimuli. Indeed, the behavioral consequences of modifying cannabinergic signaling have been
extensively documented.
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Generally, CB1R antagonism has anxiogenic effects. These effects have been observed in
multiple rodent models of anxiety across several behavioral paradigms that measure different
facets of anxiety such as the light/dark box (LDB), elevated plus maze (EPM), and social
investigation test (Litvin, Phan, Hill, Pfaff, & McEwen, 2013; O’Brien et al., 2013; Patel &
Hillard, 2006; Simone, Green, Hodges, & McCormick, 2015). CB1R antagonism can also have
anxiolytic effects, as illustrated by AM251 (CB1R antagonist) induced anxiolytic-like behaviors
in marmosets in open-field (OF) tests (Cagni & Barros, 2013). However, some researchers posit
that CB1R antagonism has no effects on anxiety-like behaviors (Hakimizadeh, Oryan,
Moghaddam, Shamsizadeh, & Roohbakhsh, 2012). Importantly, much of the therapeutic
potential of CBs is associated with CB1R agonism. Drugs that directly stimulate CB1Rs or
increase eCB levels (e.g., eCB enzyme inhibitors and eCB transport inhibitors) promote
anxiolytic-like behaviors in rodents in the EPM and LDB (Campos & Guimarães, 2009; Fogaҫa,
Aguiar, Moreira, & Guimarães, 2012; Hakimizadeh et al., 2012; Zaitone, El-Wakeil, & Abou-ElEla, 2012). Augmented cannabinergic signaling also impairs the acquisition of fear memories
and enhances fear extinction learning (Marsicano et al., 2002; Nasehi, Hajian, Ebrahimi-Ghiri, &
Zarrindast, 2016; Simone, Green, Hodges, & McCormick, 2015). In humans, anxiolysis,
enhanced fear extinction learning, and reduced activity in neural fear circuits occurs in response
to cannabidiol (CBD) administration (FAAH inhibitor; Bergamaschi et al., 2011; Das et al.,
2013; Fusar-Poli et al., 2009). These studies indicate that CB1R agonism effectively reduces
anxiety. Importantly, indirect CB1R activation shows the most therapeutic potential.
Unlike direct CB1R agonists, FAAH inhibitors do not adversely affect learning, memory,
or cognitive functioning (Hasanein & Far, 2015; Kangas et al., 2015; Varvel, Cravatt, Engram, &
Lichtman, 2006). FAAH inhibitors also lack reinforcing effects; therefore, they may not
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facilitate the development of drug dependence (Gamage et al., 2015; Murillo-Rodríguez,
Palomero-Rivero, Millán-Aldaco, & Di Marzo, 2013; Valchou, Nomikos, & Pangais, 2006).
Based on the aforementioned observations, FAAH inhibitors can produce anxiolytic effects
without significant adverse central side-effects. However, research indicates that elevated CB1R
signaling increases novelty-seeking behavior in rodents (Lafenêtre, Chaouloff, & Marsicano,
2009; Schneider et al., 2015). It is possible that enhanced AEA tone following FAAH inhibition
could have similar influences on novelty-seeking. Therefore, enhanced novelty-seeking behavior
and increased impulsivity are potential adverse side effects of drugs that block FAAH activity.
Drug dosing may also be problematic in CB-based pharmacotherapies. CB1R agonists produce
dose-dependent effects where lower doses are anxiolytic and higher doses are anxiogenic (Patel
& Hillard, 2006). Such biphasic effects are partially due to the dose-dependent modulation of
glutamatergic and γ-aminobutyric acid (GABA) signaling. Low doses of CBs inhibit
glutamatergic neurons, which results in anxiolytic effects, whereas high doses inhibit
GABAergic neurons, which results in anxiety (Rey, Purrio, Viveros, & Lutz, 2012). These
effects can also be attributed to activation of transient receptor potential vanilloid type 1 channel
(TRPV1).
TRPV1 Channel Activity in Anxiety
TRPV1s are Ca2+, Mg2+, and Na+ permeable ion channels that are located on both
presynaptic and postsynaptic neurons, and are predominantly localized on glutamatergic neurons
(Caterina et al., 2000; Iannotti et al., 2014; Kauer & Gibson, 2009; Marinelli et al., 2007).
Stimulation of TRPV1 receptors evokes glutamatergic signaling that, in turn, enhances
neurotransmission (Marinelli et al., 2003, 2007). Currently, 3 classes of endogenous TRPV1
ligands (i.e., endovanilloids [eVDs]) have been identified: hydroperoxyeicosatetraenoic acids
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(HPETEs), N-acyldopamines (NADAs), and AEA (Kauer & Gibson). Additionally, TRPV1s
can be activated by exposure to heat, acids, and the phytocannabinoids cannabidivarin (CBDV)
and CBD (Caterina et al., 2000; Iannotti et al., 2014). TRPV1 signaling has been implicated
primarily in nociception; however, these receptors have recently been shown to modulate
anxiety-like behaviors. For example, research suggests that TRPV1 agonism elicits anxiogeniclike behaviors, whereas TRPV1 antagonism has anxiolytic effects (Fogaça, Aguiar, Moreira, &
Guimarães, 2012; Hakimizadeh et al., 2012; Marsch et al., 2007 Micale et al., 2009; Terzian,
Aguiar, Guimarães, & Moreira, 2009). Impaired fear memory acquisition and enhanced fear
extinction learning following TRPV1 antagonism or conditional knockout have also been
reported (Genro, de Oliveira Alvares, & Quillfeldt, 2012; Laricchiuta, Centonze, & Petrosini,
2013; Marsch et al., 2007; Terzian, dos Reis, Guimarães, Corrêa, & Resstel, 2014).
Currently, we understand that CB1R and TRPV1 cross-talk modulates neurotransmission.
The functioning of both receptor types is endogenously linked, as AEA is an agonist of both
CB1Rs and TRPV1s. Furthermore, AEA’s efficacy in inducing active TRPV1 conformations is
similar to capsaicin, a TRPV1 agonist (Kauer & Gibson, 2009; Smart et al., 2000). Exogenous
CBs such as CBD and CBDV are also able to bind TRPV1s to elicit activation and subsequent
desensitization of channel proteins (Iannotti et al., 2014). The eVD NADA is able to bind to
CB1Rs as well as TRPV1s to differentially influence neurotransmission (Marinelli et al., 2007).
In general, binding of eCBs or eVDs to CB1Rs produces an inhibitory effect on
neurotransmission, whereas binding of these ligands to TRPV1s produces an excitatory effect
typically through modification of Ca2+ efflux and glutamatergic signaling (Hermann et al., 2003;
Smart et al., 2000; Marinelli et al., 2003, 2007). The functional relationships between CB1Rs
and TRPV1s are further illustrated by their co-localization in numerous brain regions. CB1Rs
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and TRPV1s are co-expressed in areas involved in emotional processing, production of emotional
behaviors, and cognition such as the amygdala, cerebellum, hippocampus, prefrontal cortex
(PFC), and periaqueductal grey (PAG; Cristino et al., 2006; Fogaça et al., 2012; John & Currie,
2012). The molecular, spatial, and functional links between CB1Rs and TRPV1s suggests that
they may work in tandem to regulate anxiety-like behaviors.
Fogaça et al. (2012) found that intra-dorsolateral PFC (dlFC) co-administration of
arachidonyl-2’-chloroethylamide (ACEA; direct CB1R agonist) and AM251 (CB1R antagonist)
elicited anxiogenic-like behaviors in the elevated plus maze (EPM) and Vogel conflict tests in
Wistar rats. When ACEA and the TRPV1 antagonist 6-I-CPS were co-administered, however,
anxiolytic-like behaviors were induced in both tests. The authors suggest that sequestration of
CB1Rs by AM 251 forced ACEA to bind to TRPV1s, which produced an anxiogenic-like effect.
Conversely, sequestration of TRPV1s by 6-I-CPS directed ACEA to bind to CB1Rs, producing an
anxiolytic effect. Therefore, CB1Rs and TRPV1s have contrasting roles in modulating anxietylike behaviors (Fogaça et al., 2012). Similar results have been reported regarding the opposing
functions of CB1Rs and TRPV1s in panic-like behaviors and fear extinction learning (Casarotto
et al., 2012; Laricchiuta et al., 2013). As such, the dual FAAH/TRPV1 inhibitor N-arachidonoyl
serotonin (AA-5-HT) has been used to further examine whether simultaneously modulating
CB1R and TRPV1 signaling could be a viable treatment for anxiety symptoms.
AA-5-HT
AA-5-HT has accrued some support for its potential as an anxiolytic drug. Micale et al.
(2009) found that AA-5-HT administration in male C57BL/6J (B6) mice elicited anxiolytic-like
behaviors in the EPM; furthermore, AA-5-HT appeared to be more effective than URB597
(FAAH inhibitor) in inducing such behaviors. Co-administration of AM 251 reversed the
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anxiolytic effects to anxiogenic effects presumably by redirecting eCBs to TRPV1s.
Additionally, co-administration of SB366791 (TRPV1 antagonist) enhanced the anxiolytic effects
of AA-5-HT, whereas such effects were abolished by olvanil (TRVP1 agonist) and AA-5-HT coadministration. Considering Micale et al.’s (2009) results, it is clear that AA-5-HT works by
directing the enhanced levels of eCBs to CB1Rs by blocking TRPV1 binding. However, Swiss
mice did not respond to acute AA-5-HT administration as ascertained by persistent anxiogeniclike behaviors in the EPM. Chronic AA-5-HT treatment was necessary to produce anxiolyticlike behaviors in this strain (Micale et al., 2009). Still, intra-basolateral amygdala (BLA) AA-5HT administration has produced anxiolytic effects in Sprague-Dawley rats in the EPM,
indicating consistent behavioral effects across species (John & Currie, 2012). Given that the
effects of CB1R signaling modulation are highly context-dependent, it is likely that AA-5-HT
shares this property (Haller, Varga, Ledent, Barna, & Freund, 2004). As such, investigation of
whether the anxiolytic effects of AA-5-HT seen in the EPM manifest in other behavioral
contexts is warranted. Additionally, due to the central role of the BLA in anxiety-like behaviors
and fear conditioning (e.g., associating sensory stimuli with aversive experiences), investigating
the effects of AA-5-HT administration on neurotransmission in this region would provide further
understanding of the mechanisms through which AA-5-HT affects anxiety-like behaviors
(Adolphs, 2013; Davis & Whalen, 2001).
Intra-Basolateral Amygdala Neurotransmission and Anxiety-Related Behaviors
The neural connectivity of the BLA highlights its significant role in regulating emotional
behaviors. Sensory information received from the prefrontal cortex (PFC) and thalamic afferents
is processed in the BLA, and subsequent BLA glutamatergic principal neurons activate the
central nucleus of the amygdala (CeA) from which efferent processes target downstream brain
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regions that are involved in regulating autonomic/neuroendocrine (i.e., hypothalamus) and
behavioral (i.e., striatal and brain stem regions) responses to aversive stimuli (Davis, 1992;
McDonald, 1998). Additionally, activation of direct reciprocal glutamatergic connectivity
between the BLA and hippocampus is a necessary component of associative learning in fearinducing contexts (Ikegaya, Hiroshi, & Abe, 1995; Maren & Fanselow, 1995). Cortical control
of amygdalar activation and related emotional responses is exerted through activation of
amygdalar GABAergic interneurons by medial prefrontal cortex (mPFC) glutamatergic afferents;
furthermore, mPFC activity can be modulated by BLA glutamatergic efferents that synapse onto
mPFC GABAergic interneurons and glutamatergic principal cells (Cho, Deisseroth, &
Bolshakov, 2013; Floresco & Tse, 2007; Rosenkranz & Grace, 2002). Generally, the balance
between excitatory and inhibitory activity in the BLA influences the anxiety state of an
organism.
Enhanced glutamatergic signaling elicits anxiogenic-like behaviors whereas increased
GABAergic activity has anxiolytic effects (Sajdyk & Shekhar, 1997a, 1997b; Truitt, Johnson,
Dietrich, Fitz, & Shekhar, 2009). Within the amygdala, cannabinergic signaling inhibits both
glutamatergic and GABAergic activity, causing depolarization induced suppression of excitation
(DSE) and depolarization induced suppression of inhibition (DSI), respectively (Azad et al.,
2003; Kamprath et al., 2011). Within the BLA in particular, such cross-talk may be a
mechanism through which eCBs influence conditioned fear- and anxiety-like behaviors.
Importantly, CB1Rs are densely localized within the BLA (Katona et al., 2001). Given that eCBs
are released following exposure to conditioned stimuli associated with aversive experiences,
cannabinergic signaling in this region serves a compensatory function in conditioned fear
(Marsicano et al., 2002). Indeed, intra-BLA CB1R activation enhances fear extinction learning
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(Nasehi et al., 2016). This likely occurs through CB1R activation-induced long-term depression
of inhibition (LTDi) at GABAergic synapses, which may disinhibit BLA neural systems involved
in fear extinction learning (Azad et al., 2004). Research indicates that intra-BLA CB1R agonism
also elicits anxiolytic-like behaviors; conversely, intra-BLA CB1R antagonism elicits
anxiogenic-like behaviors (Dono & Currie, 2012; John & Currie, 2012). These effects are
elicited by changes in BLA activity due to CB1R mediated modulation of glutamatergic signaling
(e.g., DSE; Hill et al., 2013; Shin et al., 2010). However, the anxiolytic effects of intra-BLA
CB1R activity could also be influenced by cross-talk with dopaminergic systems.
Researchers suggest that anxiolytic effects associated with CB1R agonists require
dopaminergic acitivity within the amygdala (Zarrindast, Mahboobi, Sadat-Shirazi, & Ahmadi,
2011a). As such, there is a clear interaction between these two systems within the amygdala
leading to the modification anxiety-like behaviors. Yet little is known about the effects of CBs
on DA efflux in specific amygdalar subnuclei. The BLA is part of the mesolimbic dopaminergic
system and is innervated by the medial forebrain bundle (MFB) upon which dopaminergic
projections from the ventral tegmental area (VTA) and substantia nigra pars compacta (SNpc)
converge (de la Mora, Gallegos-Cari, Arizmendi-García, Marcellino, & Fuxe, 2010). Much like
CB1Rs, dopamine (DA) receptor types 1, 2, and 3 (D1/2/3Rs) are localized on GABAergic
interneurons (i.e., local interneurons and paracapsular intercalated cells) in the BLA, albeit in
low to moderate volumes (de la Mora et al., 2010; Diaz, Chappell, Christian, Anderson, &
McCool, 2011; Marowsky, Yangawa, Obata, & Vogt, 2005; Rosenkranz & Grace, 2002). Local
BLA GABAergic interneurons are inhibited by dopaminergic signaling; additionally,
dopaminergic activity reduces feedforward inhibition of the BLA by the mPFC by inhibiting
paracapsular intercalated cells (de la Mora et al., 2010; Diaz et al., 2011; Marowsky et al., 2005).
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Therefore, the inhibition of GABAergic signaling by DA can promote BLA activation, which
consequently influences the expression of fear- and anxiety-like behaviors (de la Mora et al.,
2010). Elevated intra-BLA DA activity has been shown to promote the learning of fear
associations, inhibit the extinction of fear memories, and block CB1R agonism-induced fear
learning deficits; conversely, inhibition of DA signaling blocks the learning and retention of fear
associations (Borowski & Kokkindis, 1998; Greba & Kokkindis, 2000; Nader & LeDoux, 1999;
Nasehi et al., 2016; Yokoyama et al., 2005). Similarly, intra-BLA antagonism of D1/2/3Rs elicits
anxiolytic-like behaviors in the LDB and EPM (Diaz et al., 2011; Zarrindast, Sroushi, Bananej,
Vousooghi, & Hamidkhaniha, 2011b). Given that both eCBs and DA modulate BLA activity
and the subsequent expression of fear- and anxiety-like behaviors, the interaction between
cannabinergic and dopaminergic signaling within the BLA warrants further investigation.
Current Study
Our research assessed whether FAAH/TRPV1 inhibition could be used as a treatment for
anxiety symptoms. Specifically, we aimed to describe the effects of AA-5-HT administration on
anxiety-like behaviors in distinct anxiogenic contexts across mouse strains with varying degrees
of basal anxiety. Additionally, we examined AA-5-HT’s influences on fear extinction learning.
We also aimed to identify a possible neural substrate related to these effects, namely the
interaction between cannabinergic and dopaminergic systems within the BLA.
First, we examined the influences of acute AA-5-HT administration on anxiety-like
behaviors in male B6 and BALB/cJ (BCJ) mice in the LDB and OF. These tests were used to
identify context-dependent effects of AA-5-HT on anxiety-like behaviors because they are
distinct anxiogenic contexts (Kulesskaya & Voikar, 2014; Prut & Belzung, 2003). The use of B6
and BCJ mice allowed between-strain comparisons of AA-5-HT administration’s effects on
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anxiety-like behaviors in mice that differ in baseline anxiety (Brinks, van der Mark, de Kloet, &
Oitzl, 2014; Carola, D’Olimpio, Brunamonti, Mangia, & Renzi, 2002; Griebel, Belzung,
Perrault, & Sanger, 2000). We hypothesized that AA-5-HT treatment would elicit anxiolyticlike behaviors in the LDB, and OF in B6 and BCJ mice. We also investigated the effects of
FAAH/TRPV1 inhibition on fear extinction learning using a fear conditioning task (FC) where
we hypothesized that AA-5-HT administration would enhance fear extinction learning in B6 and
BCJ mice.
Next, we determined whether systemic FAAH\TRPV1 blockade affects dopamine release
in the BLA and nucleus accumbens (NAc). We used fixed potential amperometry (FPA) to
record dopamine efflux within the BLA and NAc of B6 and BCJ mice in response to electrical
stimulation of the ventral tegmental area (VTA) following systemic AA-5-HT treatment. FPA
reliably measures dopamine release in areas such as the NAc, prefrontal cortex (PFC), and
striatum with high temporal resolution (10,000 samples/s) allowing for real time measurement of
dopamine release in vivo (Forster & Blaha, 2003, Lee et al., 2006; Lester, Miller, & Blaha, 2009;
Mittleman, Goldowitz, Heck, & Blaha, 2008). FPA has also been pharmacologically confirmed
to specifically measure dopamine oxidation currents (Lee et al., 2006; Mittleman et al., 2008).
The majority of mesolimbic dopaminergic axons projecting to the BLA originate in the VTA;
additionally, stimulation of these projections elicits DA release in the NAc (de la Mora et al.,
2010; Fielding et al., 2013). Therefore, the VTA serves as a suitable stimulation site to evoke
DA release in the BLA and NAc. We hypothesized that AA-5-HT treatment would attenuate
dopamine release in the BLA and NAc of B6s and BCJs.
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Methods
Animals
Six-week-old male B6 (n = 56) and BCJ (n = 56) mice were obtained from the Jackson
Laboratory (Bar Harbor, ME). Only male mice were used in our experiments. Upon arrival,
mice were group housed (5 per cage) in 18.5 x 29.5 cm polycarbonate Generic Static
Microisolators with Sani-Chips bedding (Harland Teklad) in our laboratory (24oC average
temperature; 26% humidity) and allowed to habituate for 1 week prior to testing. Mice were
acclimated to a reverse 12:12 h light/dark cycle with lights off at 08:00 and lights on at 20:00.
Food and water were available ad libitum. All behavioral testing occurred between 08:00 and
14:00. Before behavioral testing, B6 and BCJ mice were moved to individual holding cages to
await drug administration. They were returned to their home cages after data collection was
completed. All mice were tested between 7 and 11 weeks of age. Upon completion of all
behavioral tests, mice were allowed a 1 week drug wash-out period before electrochemical
experiments were performed.
Drugs
For behavioral testing, AA-5-HT, ACEA, and dimethyl sulfoxide (DMSO), were
obtained from Sigma-Aldrich (St. Louis, MO). AA-5-HT and ACEA were dissolved in a vehicle
of 10% DMSO and saline. AA-5-HT (1 mg/kg), ACEA (1 mg/kg), or vehicle was administered
via intraperitoneal (i.p.) injection in a volume of 1 mL/kg 30 minutes before testing began.
These doses of AA-5-HT and ACEA were chosen based on previous research indicating their
efficacy in influencing anxiety- and stress-related behaviors in mice (Micale et al., 2009;
Rutkowska & Jachimczuk, 2004).
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For stereotaxic surgeries and FPA experiments, urethane was obtained from SigmaAldrich. Urethane was dissolved in distilled H2O. Prior to stereotaxic surgery, mice were
anaesthetized with an i.p. injection of urethane (1.5 g/kg). AA-5-HT (1 mg/kg), ACEA (1
mg/kg), or vehicle (1 mL/kg) was administered following a 5 min. baseline recording via i.p.
injection.
Light/Dark Box, Open Field, and Fear Conditioning Apparatus.
The LDB, OF, and FC tests were conducted using the HamiltonKinder SmartFrame™
(HamiltonKinder, Poway, CA). The SmartFrame™ included a 4 X 8 photo beam strip and a 4 X
8 photo beam rearing attachment. The LDB insert measured 24.13 cm (width) X 45.72 cm
(length). Half of the insert was made of clear Plexiglas, and the other half consisted of black
Plexiglas. The light half was illuminated by a lamp with a 15-W bulb. A manual guillotine door
made of black Plexiglas separated the two halves of the insert. For fear conditioning, a 24.13 cm
x 22.86 cm insert with a grid floor attached to a shock generator was used. A 5-W light source
and a speaker connected to a sound generator were attached to the top of this insert. Behavioral
data was recorded using MotorMonitor version 4.14 (Hamilton Kinder, Poway, CA).
Behavioral Testing
On test days, each selected mouse was moved to an individual holding cage, transferred
to the testing room, and allowed to habituate for 45 min. Holding cages were placed in cabinets
to avoid inadvertent exposure to stimuli associated with testing paradigms (i.e., light for LDB;
tone for FC). Following the habituation period, each mouse received its respective treatment
(AA-5-HT, ACEA, or vehicle). The appropriate drug was administered to each mouse 30
minutes before testing began. This provided time for the drugs to become behaviorally active.
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Mice were then exposed to LDB, OF, or FC tests depending on the test day. Behavioral tests
were separated by a 1 week interval.
Light/Dark Box. At the start of each 10 minute test, a mouse was placed in the
illuminated half of each LDB. Manual guillotine doors separating the light and dark halves of
the inserts were removed at the start of the test, allowing mice to move freely between
compartments. The locomotor activity of mice was automatically tracked by the system based
on sequences of photo beam breaks. The percentage of time spent in the light compartment,
percentage of time spent in the dark compartment, total distance traveled, and number of rears
were recorded for each mouse. Anxiolytic- and anxiogenic-like behaviors were indicated by
increases in the percentage of time spent in the light compartment and the percentage of time
spent in the dark compartment, respectively. Rearing was considered an index of exploratory
behavior. General exploration was indicated by the total distance traveled. At the end of each
test, mice were returned to their home cages. The LDBs will be cleaned with isopropyl alcohol
(70% v/v) and allowed to dry between tests.
Open Field. At the beginning of each 20 min. test, each mouse was placed in the center
of the OF. Subsequent behavior including time spent in the center of the OF, time spent in the
margins of the OF, total distance traveled, and rears were evaluated based on infrared beam
breaks as described above for LDB. Anxiolytic-like behaviors were determined by the amount
of time mice spend in the center of the OF, anxiogenic-like behaviors were indicated by the
amount of time mice spend in the margins of the OF, number of rears was an index of
exploratory behavior, and the total distance traveled indicated locomotor activity. The central
area of the OF measured 9 cm x 10 cm as specified in the software’s zonemap function. This
area was positioned 4.5 cm from the left and right walls and 15 cm from the front and back walls

14

of the OF. At the end of each session, the test mouse was returned to its home cage and the OF
was cleaned with isopropyl alcohol (70% v/v) and allowed to dry.
Fear Conditioning. Fear conditioning and extinction test parameters were based on those
used by Cook et al. (2007) and Simone et al. (2015). During training, mice were placed in the
center of the FC chamber and given a 3 min. habituation period. Following habituation, mice
received 3 pairings of an 85 dB tone (10 s duration) and a 0.36 mA foot shock. Foot shocks were
delivered during the last 2 s of tone presentation. Each pairing was separated by a 1 min.
interval. Mice were removed from the chambers 1 min. after the final presentation and returned
to their home cages. Fear extinction tests occurred 24 h after initial training. The context of the
FC chamber was altered during these tests by: covering the grid floor with a grey tile, covering
chamber walls with a black Plexiglas insert, and attaching a small container of diluted orange oil
to the top corner of the chamber (Cook et al., 2007). This ensured that conditioned freezing
responses were being elicited by the auditory stimulus and not the test chamber itself. Test mice
were administered their respective treatment (AA-5-HT, ACEA, or vehicle) 30 minutes before
fear extinction tests began. Tests started with a 3 min. habituation period followed by 22
presentations of the 85 dB tone (10 s duration) alone (CS-). Each presentation was separated by
a 1 min. inter-stimulus interval. Mice were returned to their home cages 1 min. following the
final presentation. Conditioned freezing during the first 3 min. of extinction tests served as an
index of generalized fear-like behavior. Fear extinction learning was indicated by a decrease in
conditioned freezing behavior following repeated presentations of the CS-. FC chambers will be
cleaned with isopropyl alcohol (70% v/v) and allowed to dry between tests.
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Statistical Analyses for Behavioral Tests
Mouse strains were analyzed separately due to a priori knowledge of differences in
anxiety (Brinks, van der Mark, de Kloet, & Oitzl, 2014; Griebel, Belzung, Perrault, & Sanger,
2000). Our α was set at 0.05 for all analyses. Tukey’s Honest Significant Difference (HSD) or
Bonferroni post-hoc tests were used to explore significant group differences when appropriate.
Light/Dark Box. A one-way ANOVA with treatment group (AA-5-HT, ACEA, vehicle,
and control) as a between-subjects independent variable (IV) and % of time spent in the dark
compartment, distance traveled, and number of rears as dependent variables (DVs) was used to
assess the impact of drug administration on anxiety-like behavior and gross locomotor activity in
the LDB.
Open-Field. For the OF, a one-way ANOVA with treatment group as a between-subjects
IV and % time spent in the central area of the chamber, total distance traveled, and number of
rears served as DVs was used to assess the influence of drug challenges on anxiety-related
behaviors and locomotor activity.
Fear Extinction. First, a one-way ANOVA with treatment group (between-subjects IV)
and total beam breaks, distance traveled, rears, % change in beam breaks vs. baseline, and %
change in distance traveled vs. baseline (100%; DVs) was used to assess general fear-like
responses to the altered test context. Next, a two-way repeated measures ANOVA with
treatment group and test block as between- and within-subjects IVs, respectively, and the %
change in movement during 10 s CS- tone presentations vs. baseline movement during the 10 s
preceding tone presentations over the remainder of the test (approximately 27 minutes analyzed
in 4 400s blocks) as DVs.
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Fixed Potential Amperometry
Apparatus. FPA equipment consisted of a concentric bipolar stimulating electrode (SNE100; Rhodes Medical Co., CA), a stainless steel auxiliary and silver/silver chloride reference
electrode, a carbon fiber recording microelectrode (500 μm length x 7 μm o.d.; Thornel Type P,
Union Carbide, PA), and electrode carriers mounted on a stereotaxic frame (David Kopf
Instruments, CA). The setup was encompassed by a faraday cage to minimize electrical noise.
A stimulator (Iso-Flex/Master-8, AMPI, Israel) was used to apply an electrical current to the
target brain region. DA oxidation currents were recorded using an electrometer (e-corder 401
and Picostat, eDAQ Inc., CO) and sent to a computer (see Figure 2).
Procedure. Mice were permanently anaesthetized using a 1.5 g/kg dose of urethane.
Urethane doses were split into two i.p. injections separated by an interval of 10 min. Fifteen
min. following the second injection, anesthesia was confirmed by checking eyeblink, mild tail
pinch, and mild foot pinch reflexes. Mice were then placed in a stereotaxic frame where body
temperature was kept at approximately 37oC. A stimulating electrode was inserted into the left
VTA (coordinates in mm from bregma: AP + 3.3, ML + 0.3, and DV - 4.0 from dura; Paxinos &
Franklin, 2001). A reference/auxiliary electrode combination was then placed in contact with
cortical tissue contralateral to the stimulating electrode (-3.0 mm from bregma). Next, carbonfiber recording microelectrodes were implanted into the left BLA (coordinates in mm from
bregma: AP + 1.1, ML + 2.7, DV - 5.0 from dura) or NAc (AP - 1.5, ML + 1.0, DV - 4.0)
(Paxinos & Franklin, 2001). For FPA recordings, a fixed + 0.8 V current was continuously
applied to the recording electrode positioned within the BLA or NAc. Subsequent dopamine
oxidation currents were monitored by an electrometer (filtered at 50 Hz). An i.p. injection of
AA-5-HT (1 mg/kg), ACEA (1 mg/kg), or saline was administered to each mouse after a 5 min
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baseline recording of VTA stimulation-induced dopamine release was obtained. Following drug
administration, electrically evoked dopamine oxidation currents were recorded for 90 m.
Post-fixed potential amperometry procedures. Following each FPA experiment, an iron
deposit was created to mark the stimulating electrode site by sending direct anodic current (100
μA for 10 s) through the electrode. Mice were then euthanized using a lethal intracardial
injection of urethane (0.345 g/mL). Brains were removed and stored in a 30% sucrose / 10%
formalin solution with 0.1% potassium ferricyanide for sectioning later. At -20oC using a
cryostrat, coronal sections of brains were sliced and electrode placements were identified using a
light microscope and marked on coronal diagrams (Paxinos & Franklin, 2001). In vitro electrode
calibration was accomplished by exposing each carbon-fiber recording microelectrode to known
solutions of DA (0.2 μM – 1.2 μM) via a flow injections system (Dugast, Suaud-Chagny, &
Gonon, 1994).
Statistical Analyses for Fixed Potential Amperometry Experiments
Dopamine oxidation current recordings were used to quantify VTA stimulation-induced
dopamine release in the BLA and NAc by extracting data points occurring between 0.25 s preand 10 s post-stimulation at 5 min intervals (19 total time points). Dopamine half-life was
calculated by subtracting the time point at which the signal returned to baseline from peak minus
the time at which peak dopamine release occurred divided by 2. Data from in vitro calibrations
of recording electrodes were used to convert the mean change in dopamine oxidation current
(nA) to a mean concentration (μM). Changes in the concentration of dopamine release was
expressed as an average percent change relative to baseline release (100%) at time point 1. A
two-way repeated measures ANOVA was used to assess the impact of treatment group (betweensubjects IV) and time point (within-subjects IV) on mean % change in dopamine release and %
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change in dopamine half-life at sample time points (DVs) in the BLA and NAc of B6 and BCJ
mice. A one-way ANOVA with treatment group as a between-subjects IV and % change in peak
dopamine release at sample time points as DVs was used to identify the sample time points at
which significant treatment group differences occurred. Significant group differences indicated
by p < 0.05 were further explored using Tukey’s HSD post-hoc tests when appropriate. All
statistical analyses were conducted using IBM SPSS Statistics 23 (IBM Corp).
Results
Light/Dark Box
To test the effects of enhanced cannabinergic signaling on anxiety-like behavior, mice
were administered AA-5-HT, ACEA, or vehicle (see Table 1) and exposed to the LDB for 10
min.
B6 Mice. A one-way ANOVA indicated no main effects of treatment group on the % of
time spent in the dark compartment (F (3, 36) = 1.70, p = 0.18), rearing (F(3, 36) = 2.37, p = 0.08),
and distance traveled (F (3,36) = 2.21, p = 0.10) in the LDB in B6 mice (see Table 2).
BCJ Mice. A one-way ANOVA revealed no main effect of treatment group on the % of
time BCJ mice spent in the dark half of the LDB (F (3, 36) = 1.27, p = 0.29; see Table 2).
However, a main effect of treatment group on rearing was reported (F(3, 36) = 4.54, p = 0.00, ɳp2 =
0.27). Post-hoc Tukey HSD tests indicated that AA-5-HT administration significantly increased
rearing (M = 42.5, SEM = ± 10.1) relative to control (M = 14.2, SEM = ± 7.7, p = 0.04), vehicle
(M = 11.1, SEM = ± 5.2, p = 0.02), and ACEA groups (M = 10.3 SEM = ± 4.2, p = 0.01) whereas
ACEA administration did not modify rearing behavior (see Figure 3). The one-way ANOVA
also showed a main effect of treatment group on total distance traveled in BCJs (F(3, 36) = 3.53, p
= 0.02, ɳp2 = 0.22). Tukey HSD post-hoc analyses found that AA-5-HT injections significantly
increased the total distance traveled (M = 934.1 cm, SEM = ± 135.97 cm) relative to control mice
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(M = 473.9 cm, SEM = ± 92.39 cm, p = 0.03); additionally, AA-5-HT treatment elicited a trend
toward increased motor activity in comparison to vehicle (M = 495.40 cm, SEM = ± 87.93 cm, p
= 0.051) and ACEA (M = 541.10 cm, SEM = ± 136.17 cm, p = 0.09) treated mice. However,
ACEA administration did not influence overall locomotor activity in BCJs compared to control
and vehicle groups (see Figure 3). To determine whether increased rearing in BCJs was due to
enhanced gross locomotor activity, we used an analysis of covariance (ANCOVA) with
treatment group as a between-subjects IV, total rears as a between subjects DV, and total
distance traveled as a covariate. Analyses found no significant treatment group main effect on
rearing behavior when controlling for total distance traveled (F (3, 35) = 1.28, p = 0.29).
Open Field
The OF was used to assess the effects of AA-5-HT and ACEA treatments on anxiety-like
behaviors in a context that is distinct from the LDB (see Table 1).
B6 Mice. A one-way ANOVA found no main effects of treatment group on the percent
of time spent in the center of the chamber (F (3, 50) = 0.22, p = 0.87), rearing (F (3, 50) = 0.93, p =
0.42), and distance traveled (F (3, 50) = 0.25, p = 0.87) in B6 mice in the OF (see Table 2).
BCJ Mice. Similarly, analyses showed no main effects of treatment on percent time spent
in the center of the arena (F (3, 45) = 1.53, p = 0.21) and rearing (F (3, 45) = 2.36, p = 0.08) in the
OF in BCJ mice (see Table 2). However, AA-5-HT treated BCJs showed a trend toward
increased rearing behavior (M = 40.28, SEM = ± 9.82) relative to those that were given ACEA
(M = 5.18, SEM = 1.01, p = 0.051). No significant main effects of treatment on total distance
traveled were indicated for BCJs (F (3, 45) = 2.34, p = 0.08; see Table 2). Although, ACEA
treated mice did show a trend toward decreased locomotor activity (M = 803.63 cm, SEM = ±
87.25 cm) relative to AA-5-HT treated BCJs (M = 1343.42 cm, SEM = ± 152.62 cm, p = 0.06).
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Fear Extinction
Fear conditioning and extinction tests were used to determine whether AA-5-HT and
ACEA treatments influence generalized fear and fear extinction learning (see Table 1).
B6 Mice. A one-way ANOVA indicated a significant main effect of treatment group on
total beam breaks (F (3, 55) = 13.48, p = 0.00, ɳp2 = 0.43), distance traveled (F (3, 55) = 14.01, p =
0.00, ɳp2 = 0.44), rears (F (3, 55) = 5.75, p = 0.00, ɳp2 = 0.24), % change in beam breaks vs.
baseline habituation (F (3,55) = 5.74, p = 0.00, ɳp2 = 0.24), and % change in distance traveled vs.
baseline habituation (F (3, 55) = 5.64, p = 0.00, ɳp2 = 0.24). Post-hoc Tukey’s HSD analyses
showed that vehicle and ACEA treated animals exhibited significantly reduced locomotor
activity relative to AA-5-HT treated and control animals in terms of total beam breaks, distance
traveled, and % change in beam breaks vs. baseline habituation (p < 0.05). However, B6s given
vehicle or ACEA showed significantly lower % change in distance traveled vs. baseline
habituation relative to control mice only, and they performed significantly fewer rears in the
altered test context compared to AA-5-HT treated mice only (p < 0.05; see Figure 4).
For fear extinction in B6 mice, a two-way repeated measures ANOVA revealed a
significant block main effect (F (3, 50) = 17.10, p = 0.00, ɳp2 = 0.50; see Figure 5) and a treatment
x block interaction effect (F (9, 156) = 2.13, p = 0.03, ɳp2 = 0.11; see Figure 6) on % change in
movement during CS- presentations. For the block main effect, Bonferroni post-hoc analyses
indicated that the % change in movement during CS- tones was significantly lower during test
block 1 relative to blocks 2 – 4; additionally, the % change in movement during CSpresentations was significantly higher in test block 4 compared to blocks 1 – 3 (p < 0.05).
However, there was a trend toward significant in the % change in movement during the CSbetween blocks 2 (M = 38.02 %, SEM = ± 3.17 %) and 3 (M = 48.22 %, SEM = ± 4.56 %, p =
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0.06). For the treatment group x block interaction effect, a one-way ANOVA was used to
determine during which of the 4 test blocks treatment groups differed in % change in movement
during CS- tones. The analysis indicated a significant main effect of treatment group on %
change in movement during CS- presentations during block 1 (F (3, 55) = 3.95, p = 0.01, ɳp2 =
0.18); however, no treatment group main effect was found for test blocks 2 (F (3, 55) = 0.86, p =
0.46), 3 (F (3, 55) = 0.66, p = 0.57), and 4 (F (3, 55) = 0.83, p = 0.48; see Table 3). Tukey’s HSD
post-hoc analyses showed that ACEA treated B6s exhibited a trend toward reduced % change in
movement during CS- presentations relative to control mice (p = 0.056). Additionally, mice
given vehicle showed a trend toward reduced % change in movement during CS- presentations
compared to control B6s (p = 0.08). A similar trend was also revealed for ACEA treated mice
relative to AA-5-HT treated mice (p = 0.08; see Figure 7).
BCJ Mice. A one-way ANOVA indicated no significant treatment group main effect on
total beam breaks (F (3, 49) = 1.33, p = 0.27), total rears (F (3, 49) = 0.99, p = 0.40), total distance
traveled (F (3, 49) = 0.78, p = 0.50), % change in beam breaks vs. baseline habituation (F (3, 49) =
0.37, p = 0.77), or % change in distance traveled during baseline habituation (F (3, 49) = 0.40, p =
0.75; see Table 3). For fear extinction tests, a two-way repeated measures ANOVA revealed no
main effect of block (F (3, 44) = 1.53, p = 0.21), no treatment group main effect (F (3, 46) = 1.02, p =
0.39), and no treatment group x block interaction effect (F (9, 138) = 1.03, p = 0.41) on the %
change in movement during CS- tones in BCJs for test blocks 1 – 4 (see Table 3).
Fixed Potential Amperometry
AA-5-HT and ACEA were administered during FPA experiments to evaluate the effects
of indirect and direct CB1R agonists on the percent change in evoked BLA and NAc dopamine
release (see Table 4).
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B6 Mice. In the BLA, a significant main effect of time on % change in dopamine release
(F(18, 306) = 37.79, p = 0.00, ɳp2 = 0.69) was revealed; however, no main effect of treatment group
(F(2, 17) = 0.113, p = 0.89) or time x treatment group interaction (F(36, 306) = 0.85, p = 0.70) was
reported (see Table 5).
For the NAc, a significant time x treatment group interaction (F (36, 342) = 2.23, p = 0.00,
ɳp2 = 0.19) on % change in dopamine release was observed. Treatment group differences
emerged at the 70 m time point (F (2, 19) = 4.32, p = 0.02, ɳp2 = 0.31) and persisted to the final 90
m time point (F (2, 19) = 5.62, p = 0.01, ɳp2 = 0.37). Post-hoc analyses showed that ACEA treated
B6s exhibited attenuated % change in dopamine release relative to vehicle treated mice from the
70 m time point (p = 0.03) to the 90 m time point (p = 0.03). Additionally, AA-5-HT treated B6s
showed inhibited % change in dopamine release compared to vehicle treated mice from the 80 m
time point (p = 0.04) to the 90 m time point (p = 0.01; see Figures 8 and 10). Additionally, no
significant main effect of time (F(3, 57) = 0.22, p = 0.88) or time x treatment group interaction (F(6,
57)

= 1.56, p = 0.17) on % change in dopamine half-life was found; however, there was a trend

toward significance for the treatment group main effect (F(2, 19) = 3.33, p = 0.057, ɳp2 = 0.26).
BCJ Mice. In the BLA, a significant treatment group x time interaction on % change in
dopamine release (F(36, 252) = 2.39, p = 0.00, ɳp2 = 0.25) was found. Treatment group effects
persisted from the 20 m time point (F(2, 16) = 6.85, p = 0.00, ɳp2 = 0.49) to the 90 m time point
(F(2, 16) = 7.61, p = 0.00, ɳp2 = 0.52). ACEA treated BCJs exhibited significantly attenuated %
change in dopamine release compared to vehicle treated BCJs starting at the 20 m time point (p =
0.00) and ending at the 90 m time point (p = 0.00). Additionally, BCJs given AA-5-HT showed
attenuation between the 50 m (p = 0.02) and the 90 m time point (p = 0.02; see Figures 9 and
10). A significant main effect of treatment group (F(2, 14) = 4.92, p = 0.02, ɳp2 = 0.41) on %
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change in dopamine half-life was reported. Percent change in dopamine half-life was reduced in
ACEA (M = 95.05, ±SEM = 1.31) treated BCJs relative to those administered AA-5-HT (M =
100.12, ±SEM = 1.20, p = 0.03) or vehicle (M = 99.77, ±SEM = 1.2, p = 0.04).
In the NAc, a significant main effect of time on % change in peak dopamine release (F(18,
306)

= 46.27, p = 0.00, ɳp2 = 0.73) was observed. However, no main effect of treatment group

(F(2, 17) = 2.39, p = 0.12) or treatment group x time interaction (F(36, 306) = 0.54, p = 0.98) was
found (see Table 5). Similarly, no main effect of time (F(3, 57) = 0.68, p = 0.56), treatment group
(F(2, 19) = 0.80, p = 0.46), or time x treatment group interaction effect (F(6, 57) = 0.24, p = 0.96) on
% change in dopamine half-life was reported.
Stereotaxic Placement of Stimulating Electrodes
Following amperometry experiments, the placements of stimulating electrodes (n = 79)
were determined by examining lesioned regions in sectioned mouse brains. The positions of
stimulating electrodes were localized within the anatomical region of the VTA spanning -2.92 to
– 3.88 mm AP from bregma and -4.0 to -5.0 DV from dura (see Figure 11).
Discussion
Anxiety is an adaptive process; however, it can become maladaptive when experienced in
excess in inappropriate contexts (Brosschot et al., 2016; Grupe & Nitschke, 2013). Given the
pervasiveness of anxiety-related health issues in the U.S. and the limitations of current
anxiolytics, the eCB system has become a region of interest for the development of novel antianxiety drugs. Although, the impact of contextual factors and differences in baseline anxiety on
the anxiety-related effects of cannabinoid administration is not fully understood. Our findings
suggest that contextual factors and mouse strain influence the effects of FAAH/TRPV1 inhibition
on some aspects of anxiety-related behavior in mice.
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Impact of Context and Strain on the Anxiety-Related Effects of AA-5-HT
Light/dark box. In B6 mice, AA-5-HT or ACEA administration did not influence
behavioral measures in the LDB. In BCJ mice, drug pretreatments also did not influence
anxiety-like behavior given the lack of effect of drug administration on the percentage of time
mice spent in the lit compartment of the maze. Similarly, other studies have shown that acute,
pharmacological FAAH inhibition or CB1R activation (at moderate agonist doses) does not
influence anxiety-like behavior in the LDB in rodents (Moreira, Kaiser, Monory, & Lutz, 2008;
Rutkowska, Jamontt, & Gliniak, 2006; Valjent, Mitchell, Besson, Caboche, & Maldonado,
2002). However, we observed enhanced exploration in BCJ mice following AA-5-HT treatment
as evidenced by a significant increase in rearing behavior. Although not a primary measure,
exploratory rearing behavior is considered an index of anxiolytic-like effects (Costall, Jones,
Kelly, Naylor, & Tomkins, 1989). Therefore, our findings suggest that AA-5-HT elicited modest
anxiolytic-like effects in BCJs in the LDB. These results agree with research suggesting that the
administration of AA-5-HT or other FAAH inhibitors elicits anxiolytic-like behaviors in the
LDB (Marco et al., 2015; Micale et al., 2009; Scherma et al., 2008).
In addition to increased exploration, AA-5-HT treated BCJs displayed enhanced
locomotor activity in the LDB. This is surprising given that the blockade of FAAH with AA-5HT or other inhibitors has been shown decrease or not affect locomotor activity (Kathuria et al.,
2003, Marco et al., 2015, Micale et al., 2009, Patel & Hillard, 2006; Scherma et al., 2008). Other
research has shown that the administration of low doses of a TRPV1 antagonist enhances
locomotor activity in rodent models of anxiety (Hakimizadeh et al., 2012). This suggests that the
increased exploratory behavior seen in AA-5-HT treated BCJ mice in the LDB could have been a
product of elevated locomotor activity and therefore not indicative of anxiolytic-like effects.
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Open field. AA-5-HT or ACEA pretreatment did not affect anxiety-related measures or
locomotor activity in the OF in either B6 or BCJ mice. Such findings corroborate previous
research indicating that administration of FAAH inhibitors or CB1R agonists (at moderate doses)
does not impact anxiety-related behaviors in the OF (Järbe, Andrzejewski, & DiPatrizio, 2002;
Rutkowska et al., 2006; Sulcova, Mechoulam, & Fride, 1998). Our results from this task and the
LDB emphasize the influence of context and mouse strain on the anxiety-related effects of
cannabinergic signaling. Given the involvement of fear in many anxiety-related disorders (see
APA, 2013), it is also crucial to consider whether fear-related processes are modulated by AA-5HT treatment.
Involvement of Cannabinergic Activity in General Fear
In B6 mice, examination of exploratory and locomotor behavior during the habituation
period in the altered extinction context revealed that ACEA and vehicle pretreated B6s exhibited
reduced activity. These results suggest that ACEA and vehicle treatments potentiated general
fear-like behavior in the altered context. Given that acute stressors can adversely impact fearassociated processes and that vehicle treated B6s expressed enhanced general fear-like behavior,
it is possible that the experience of stressful stimuli promoted general fear in the altered
extinction context (Izquierdo, Wellman, & Holmes, 2006; Maroun et al., 2013). Importantly,
activity during the habituation period was not adversely affected in AA-5-HT-treated B6s.
Furthermore, although CBs can have analgesic effects and modulate novelty-seeking behavior,
but it is unlikely that such effects contributed to the modulation of fear in AA-5-HT treated mice
given that this group behaved similarly to control mice in the extinction context (Elikottil, Gupta,
& Gupta, 2009; Fox, Sterling, & Van Bockstaele, 2009). Therefore, AA-5-HT administration
likely inhibited general fear-like behavior. Such findings agree with previous research
illustrating the anti-fear-like influences of eCB signaling (Stern et al., 2017).
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However, it is crucial to note that none of our treatments influenced fear extinction
learning in B6 mice. Such results corroborate other research showing a lack of effect of
cannabinergic activity on fear extinction learning (Burman et al., 2016). Although, other studies
support an integral role for cannabinergic signaling in fear extinction learning (Kamprath et al.,
2009, 2011; Marsicano et al., 2002, Nasehi et al., 2016). Such discrepancies likely arise from the
use of different methodologies (e.g., contextual vs. auditory fear condition), cannabinergic drugs,
drug doses, genetic CB1R manipulations, and/or animal strains. Additionally, it may be that
previous exposure to LDB and OF tests altered the performance of our mice in fear extinction
tests. Nevertheless, our results indicate a role for TRPV1/FAAH inhibition in the expression of
general fear-like behaviors. Critically, the effects of AA-5-HT administration on general fearlike behaviors are likely influenced by baseline anxiety levels given that measures of general
fear-like behavior were not affected by cannabinergic drug treatments in BCJ mice.
Summary of Behavioral Findings
Collectively, our results indicate that AA-5-HT administration likely elicited modest
context-dependent anxiolytic-like effects. Such effects could have been influenced by
differences in baseline anxiety given that they were only observed in BCJs which generally
exhibit higher levels of baseline anxiety than B6s (Griebel et al., 2000). However, these findings
should be interpreted with caution given that increased exploratory rearing was not statistically
significant when controlling for locomotion in BCJs. Although, strain differences in locomotor
activity did not affect other behavioral measures. This may suggest that AA-5-HT treatmentinduced modest anxiolytic-like effects in BCJ mice were not solely due to changes in gross
locomotor activity. Our findings also indicate that the anti-fear-like effects of eCB activity are
strain-dependent.
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However, it is unclear whether these modest anxiolytic- and anti-fear-like effects were
due to TRPV1 channel blockade given that TRPV1 antagonist treatments can modulate anxietyand fear-like behavior in rodents (Fogaça et al., 2012; Hakimizadeh et al., 2012; Laricchiuta et
al., 2013, Marsch et al., 2007; Terzian et al., 2009). Future studies that include TRPV1 agonist or
CB1R antagonist pretreatment followed by AA-5-HT administration are required to dissect the
contribution of these receptor types to anxiety- and fear-related processes. It is also important to
consider how changes in the activity of cannabinergic receptors impacts neurophysiological
systems that impact the expression of anxiety- and fear-like behaviors.
Effects of Cannabinoids on Evoked Mesolimbic Dopamine Release
Basolateral amygdala. AA-5-HT treatment reduced VTA stimulation-induced dopamine
release in the BLA of BCJ mice. These findings complement research demonstrating attenuated
dopamine release in the BLA following administration of anxiolytic drugs (Coco, Kuhn, Ely, &
Kilts, 1992). Studies have shown that elevated dopamine signaling in the BLA attenuates
GABAergic interneuron firing and feedforward inhibition from the mPFC, thus increasing
overall activity in the BLA which can promote anxiety-like behaviors (de la mora et al., 2010;
Diaz et al., 2011; Marowsky et al., 2005). Therefore, it is possible that attenuation of dopamine
release in the BLA could contribute to anxiolytic-like effects of cannabinoids.
Inhibited intra-BLA dopaminergic activity has also been linked to attenuated learning and
retention of fear associations in rodents (Borowski & Kokkindis, 1998; Greba & Kokkindis,
2000; Nader & LeDoux, 1999; Nasehi et al., 2016; Yokoyama et al., 2005). Our findings
indicate that administration of AA-5-HT inhibits dopamine release in the BLA of mice which
provides evidence for cannabinergic and dopaminergic interactions in this region. Such
interactions in the BLA may regulate fear-related behaviors. Future studies measuring the
consequences of AA-5-HT administration on dopamine release in the BLA of awake animals
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during acquisition and extinction of conditioned fear would be beneficial in evaluating this
possibility.
Nucleus accumbens. Previous research has demonstrated inhibition of electrically
evoked striatal dopamine release following CB1R agonist administration using fast-scan cyclic
voltammetry (Cheer, Wassum, Heien, Phillips, & Wightman, 2004; O’Neill, Evers-Donnelly,
Nicholson, O’Boyle, & O’Connor, 2009). Similarly, evoked dopamine release in the NAc was
attenuated following systemic AA-5-HT administration in our B6 mice. Conversely, AA-5-HT
treatments did not affect dopamine release in the NAc of BCJs. Most drugs of abuse enhance
phasic dopamine release in the NAc which is the central mechanism for the reinforcing
properties of these drugs (Carlezon Jr. & Thomas, 2009). Therefore, our data suggest that AA-5HT administration may not exert reinforcing effects via enhanced intra-NAc dopamine efflux.
This finding is in line with research indicating a lack of reinforcing properties of FAAH
inhibitors in other animal models (Gamage et al., 2015; Murillo-Rodríguez et al., 2013; Valchou
et al., 2006).
Summary of Electrochemical Findings
Together, our results suggest that systemic AA-5-HT administration elicited straindependent patterns of attenuated evoked mesolimbic dopamine release. Particularly, CB
administration inhibited dopamine release in the BLA of BCJs, and only this strain exhibited
reduced anxiety-like behavior. Therefore, it may be that variation in the cannabinergic
modulation of intra-BLA dopamine release contributes to anxiety-like behavioral differences
observed between BCJs and B6s. Furthermore, the lack of increased dopamine release in the
NAc following cannabinergic drug administration in either strain suggests that AA-5-HT may
not express significant abuse liability.
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Conclusion
Our results extend current research on the anxiolytic effects of FAAH/TRPV1 blockade in
several ways. First, potential differences in anxiety-related behavioral responses to AA-5-HT
administration between B6 and BCJ mice have not been examined, yet these strains are known to
differ markedly in their behavioral responses to anxiogenic stimuli (Brinks et al., 2014; Carola et
al., 2002; Griebel et al., 2000). Therefore, our description of differences in anxiety-like
behaviors in response to anxiolytic drug treatments (and behavioral contexts) assists in
establishing animal models of anxiety. Second, we assess context-dependent effects of AA-5HT on anxiety-like behaviors in the LDB and OF. This consideration is warranted due to the
sensitivity of eCB-elicited behavioral changes to contextual stimuli (Haller et al., 2004). We
also examine the effects of AA-5-HT on fear extinction learning. Given that conditioned fear
and unconditioned anxiety are distinct dimensions of anxiety disorders, it is necessary to
consider whether AA-5-HT administration can modulate fear-like as well as anxiety-like
behaviors in order to evaluate the its therapeutic potential.
To our knowledge, the influence of FAAH/TRPV1 inhibition on intra-BLA and NAc
dopamine transmission has yet to be examined. Data from FPA experiments illustrate how
cannabinergic and dopaminergic interactions in the BLA might affect anxiety-like behaviors.
Given that many drugs of abuse increase dopamine efflux in the NAc, our findings regarding
post-treatment changes in NAc dopamine release indicate that AA-5-HT administration has low
potential for reinforcing effects (Carlezon Jr. & Thomas, 2009). Overall, our findings aid in
assessing the utility of AA-5-HT as an anxiolytic and served to better characterize mouse models
of anxiety.
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However, Future research utilizing dose-response approaches, counterbalanced paradigm
exposure, chronic/sub-chronic treatment regimens, and electrochemical or electrophysiological
assessment of mesolimbic dopaminergic activity in behaving animals in distinct anxiogenic
contexts is required to fully examine the impact of AA-5-HT administration on anxiety-like
behaviors. TRPV1 agonist or CB1R antagonist and AA-5-HT co-administration would also be
beneficial for assessing the influence of vanilloidergic and cannabinergic signaling on the
anxiety- and fear-related effects of AA-5-HT administration. Given that CBs can have
amotivational effects and alter goal-directed behavior, future research could examine whether
AA-5-HT adversely impacts motivation and reward seeking to further assess its utility as an
anxiolytic (Lawn et al., 2016).
In conclusion, we suggest that acute AA-5-HT administration exhibits limited utility as a
treatment for anxiety symptoms because it only affects some aspects of anxiety-related behavior.
Additionally, the observed context- and strain- dependent nature of the effects of AA-5-HT
administration on anxiety-like behaviors may also indicate limited utility as an anxiolytic drug
given the appreciable individual differences in contextual experiences and emotional reactivity to
anxiogenic stimuli in humans. Ultimately, these individual differences are critical factors to
consider when developing CB treatments for anxiety symptoms.
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Appendix
Table 1
Group Sizes for Behavioral Tests
Strain
B6

BCJ

B6

BCJ

Group
Control
Vehicle
AA-5-HT
ACEA
Control

Test
LDB

LDB

Vehicle
AA-5-HT
ACEA
Control
Vehicle
AA-5-HT
ACEA
Control
Vehicle

OF

OF

n
10
10
10
10
10
10
10
10
13
14
14
13
12
12

AA-5-HT
14
ACEA
11
B6
Control
FC
14
Vehicle
14
AA-5-HT
14
ACEA
14
Note. B6 = C57BL/6J; BCJ = BALB/cJ; AA-5-HT = arachidonoyl serotonin; ACEA =
arachidonyl-2’-chloroethylamide; LDB = light/dark box; OF = open-field; FC = fear
conditioning.
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Table 1 (Continued)
Group Sizes for Behavioral Tests
Strain
BCJ

Group
Test
n
Control
FC
14
Vehicle
11
AA-5-HT
14
ACEA
11
Note. B6 = C57BL/6J; BCJ = BALB/cJ; AA-5-HT = arachidonoyl serotonin; ACEA =
arachidonyl-2’-chloroethylamide; LDB = light/dark box; OF = open-field; FC = fear
conditioning.
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Table 2
Non-Significant Results for Light/Dark Box and Open Field Tests
Strain
BCJ

Test
LDB

Measure
% Time in Dark Compartment

B6

Rearing (f)

Distance Traveled (cm)

BCJ

OF

% Time in Center

B6

BCJ

Rearing (f)

Treatment
AA-5-HT
ACEA
Vehicle
Control
AA-5-HT
ACEA

M
0.63
0.36
0.61
0.52
0.57
0.57

± SEM
0.50
0.09
0.33
0.26
0.01
0.03

VEH
Control
AA-5-HT
ACEA
VEH
Control
AA-5-HT
ACEA
VEH

0.62
0.53
100.8
90.9
86.0
110.1
1447.60
1459.00
1406.50

0.03
0.02
6.1
7.9
8.6
4.0
35.94
97.47
103.49

Control
AA-5-HT
ACEA
VEH
Control
AA-5-HT
ACEA
VEH
Control
AA-5-HT

1682.60
0.019
0.003
0.016
0.012
0.170
0.151
0.170
0.154
40.28

80.64
0.006
0.000
0.006
0.005
0.020
0.017
0.027
0.016
9.82

ACEA
VEH
Control

5.18
24.66
26.58

1.01
9.38
12.00

Note. BCJ = BALB/cJ; B6 = C57BL/6J; LDB = light/dark box; OF = open field; AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide.
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Table 2 (Continued)
Non-Significant Results for Light/Dark Box and Open Field Tests
Strain
B6

BCJ

Test
OF

Measure
Rearing (f)

Distance Traveled (cm)

B6

Treatment
AA-5-HT
ACEA
Vehicle
Control
AA-5-HT
ACEA

M
195.78
179.23
190.14
210.61
1343.42
803.63

± SEM
13.81
13.86
10.33
14.83
152.62
87.25

Vehicle
Control
AA-5-HT
ACEA
Vehicle
Control

1219.91
1122.50
2605.28
2553.38
2601.28
2740.23

169.58
158.66
112.37
175.80
117.92
208.05

Note. BCJ = BALB/cJ; B6 = C57BL/6J; LDB = light/dark box; OF = open field; AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide.
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Table 3
Non-Significant Results for Fear Extinction Tests
Strain
B6

Measure
% change in movement during CS-

Block
2

3

4

BCJ

beam breaks (f)

HAB

distance traveled (cm)

Treatment
Control
Vehicle
AA-5-HT
ACEA
Control
Vehicle

M
42.18
41.79
29.46
38.67
47.97
40.43

± SEM
8.34
6.83
5.01
4.48
9.52
6.88

AA-5-HT

46.17

6.77

ACEA
Control
Vehicle
AA-5-HT
ACEA
Control
Vehicle
AA-5-HT

58.31
51.97
58.66
61.80
70.63
311.78
315.63
339.21

12.20
9.73
7.25
7.00
9.60
26.84
12.42
10.77

ACEA
Control
Vehicle
AA-5-HT
ACEA

279.63
555.28
534.09
578.78
501.09

27.56
47.02
21.15
18.17
49.11

Note. B6 = C57BL/6J, CS- = non-reinforced conditioned stimulus; AA-5-HT = arachidonoyl
serotonin; ACEA = arachidonyl-2’-chloroethylamide; BCJ = BALB/cJ; HAB = habituation
period.
a

Scores represent mean % change in movement during CS- presentations across all treatment

groups (i.e., control, vehicle, AA-5-HT, ACEA).
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Table 3 (Continued)
Non-Significant Results for Fear Extinction Tests
Strain
BCJ

Measure
rears (f)

Block

% change in beam breaks vs. baseline

% change in distance traveled vs. baseline

HAB

% change in movement during CS-

1

2

3

Treatment
Control
Vehicle
AA-5-HT
ACEA
Control
Vehicle

M
41.28
44.81
43.71
35.00
248.48
257.43

± SEM
4.01
3.67
3.57
5.52
29.76
22.97

AA-5-HT
ACEA

221.70
247.67

16.70
32.08

Control
Vehicle
AA-5-HT
ACEA
Control
Vehicle
AA-5-HT
ACEA

199.40
202.26
177.65
204.42
69.95
51.15
40.24
65.83

22.16
18.15
13.47
25.67
13.54
7.39
10.24
18.59

Control
Vehicle
AA-5-HT
ACEA
Control
Vehicle

76.89
40.75
62.13
67.82
89.89
58.04

20.69
8.01
16.61
39.62
10.59
17.09

AA-5-HT
ACEA

71.13
53.51

9.11
9.05

Note. B6 = C57BL/6J, CS- = non-reinforced conditioned stimulus; AA-5-HT = arachidonoyl
serotonin; ACEA = arachidonyl-2’-chloroethylamide; BCJ = BALB/cJ; HAB = habituation
period.
a

Scores represent mean % change in movement during CS- presentations across all treatment

groups (i.e., control, vehicle, AA-5-HT, ACEA).
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Table 3 (Continued)
Non-Significant Results for Fear Extinction Tests
Strain
BCJ

Measure
% change in movement during CS-

Block
4

1
2
3
4

Treatment
Control
Vehicle
AA-5-HT
ACEA
Combineda

M
75.79
57.77
109.91
71.13
56.59
62.81

± SEM
6.67
9.14
39.90
8.90
6.51
11.36

69.63
80.35

5.95
11.69

Note. B6 = C57BL/6J, CS- = non-reinforced conditioned stimulus; AA-5-HT = arachidonoyl
serotonin; ACEA = arachidonyl-2’-chloroethylamide; BCJ = BALB/cJ; HAB = habituation
period.
a

Scores represent mean % change in movement during CS- presentations across all treatment

groups (i.e., control, vehicle, AA-5-HT, ACEA).
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Table 4
Group Sizes for Fixed Potential Amperometry Experiments
Strain
B6

DA Recording Site
BLA

NAc

BALB/cJ

BLA

NAc

–

–

Drug during DA Recording
AA-5-HT
ACEA
Vehicle
AA-5-HT
ACEA
Vehicle

N
6
7
7
6
8
8

AA-5-HT

6

ACEA
Vehicle
AA-5-HT
ACEA
Vehicle
–

5
6
6
7
7
79

Note. B6 = C57BL/6J; BCJ = BALB/cJ; DA = dopamine; BLA = basolateral amygdala; NAc =
nucleus accumbens; AA-5-HT = arachidonoyl serotonin; ACEA = arachidonyl-2’chloroethylamide.
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Table 5
Non-Significant Results for Fixed Potential Amperometry Experiments
T 30 m
T 70 m
T 80 m
T 90 m
Strain
Region
Treatment
M
± SEM
M
± SEM
M
± SEM
M
± SEM
B6
BLA
AA-5-HT
82.11
3.47
73.61
3.93
64.99
4.42
71.46
6.87
ACEA
82.22
4.26
73.66
7.13
71.53
6.36
67.54
6.01
Vehicle
84.56
5.06
68.82
7.11
66.12
6.23
62.64
7.14
BCJ
NAc
AA-5-HT
86.05
4.07
77.07
6.49
69.22
7.58
62.62
7.61
ACEA
73.28
4.07
57.16
6.49
53.66
7.58
52.25
7.61
Vehicle
84.00
4.39
68.88
7.01
64.96
8.19
60.46
8.22
Note. Values represent % change in evoked dopamine oxidation current from baseline. T = time point; B6 = C57BL/6J; BLA =
basolateral amygdala; BCJ = BALB/cJ; NAc = nucleus accumbens; AA-5-HT = arachidonoyl serotonin; ACEA = arachidonyl-2’chloroethylamide.
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Figure 1. Schematic of experiment schedule. All mice were exposed to each test in the same order. A 1 week waiting period was
used between behavioral and electrochemical experiments to prevent drug carry-over effects.
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Figure 2. Schematic of fixed potential amperometry setup. A combination auxiliary/reference electrode monitors background current
and holds brain tissue at a continuous 0.8 V potential. Carbon fiber recording microelectrodes in the basolateral amygdala (BLA) or
nucleus accumbens (NAc) to monitor dopamine oxidation currents following electrical stimulation of the ventral tegmental area
(VTA). Subsequent response traces represent the release and reuptake of dopamine.
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Figure 3. Rearing behavior and locomotor activity in the light/dark box (LDB). A. Frequency of rearing in the LDB for C57BL/6J
(B6) and BALB/cJ (BCJ) mice. B. Locomotor activity in the LDB in B6 and BCJ mice. All error bars represent ± SEM. AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide; * = p < 0.05.
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Figure 4. Behavioral measures in C57BL/6J mice during the habituation block of fear extinction
experiments. A. Frequency of beam breaks. B. Total distance traveled. C. Shows the impact
of drug treatments on the frequency of rearing. D. % change in beam breaks and distance
traveled vs. baseline habituation during training. Error bars represent ± SEM. AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide; *p < 0.05 vs. control mice; #p
< 0.05 vs. AA-5-HT treated mice.
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Figure 5. Mean percent change in movement during CS- presentations across fear extinction test
blocks in all C57BL/6J mice. The 3 habituation period is included to illustrate recall of fear
associations. CS- presentations begin at test block 1. Error bars represent ± SEM. *p < 0.05 vs.
all blocks; +p = 0.06.
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Figure 6. Mean percent change in movement during CS- presentations across fear extinction test
blocks in C57BL/6J treatment groups. The percent change in movement during the 3 min.
habituation period vs. baseline movement was included to illustrate recall of fear associations.
CS- presentations begin at test block 1. Error bars represent ± SEM. AA-5-HT = arachidonoyl
serotonin; ACEA = arachidonyl-2’-chloroethylamide; *p < 0.05.
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Figure 7. Mean percent change in movement during CS- presentations in C57BL/6J treatment
groups during block 1 of fear extinction tests. Error bars represent ± SEM. AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide; +p = 0.056; #p = 0.08.
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Figure 8. Mean percent change in dopamine release from baseline in the nucleus accumbens of
C57BL/6J mice during post-treatment amperometric recordings. The inset shows the effects of
drug treatments on ventral tegmental area stimulation-induced dopamine release at 70, 80, and
90 min. following drug or vehicle administration. Error bars represent ± SEM. AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide; T = time point, * = p < 0.05.
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Figure 9. Mean percent change in dopamine release from baseline in the basolateral amygdala
of BALB/cJ mice during post-treatment amperometric recordings. The inset shows the effects of
drug treatments on ventral tegmental area stimulation-induced dopamine release at 70, 80, and
90 min. following drug or vehicle administration. Error bars represent ± SEM. AA-5-HT =
arachidonoyl serotonin; ACEA = arachidonyl-2’-chloroethylamide; T = time point, * = p < 0.05,
+ = 0.10.
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Figure 10. Sample evoked dopamine release traces recorded at the 90 minute time point. A. – C. Shows dopamine response traces in
the basolateral amygdala following systemic vehicle or cannabinergic drug treatment in BALB/cJ mice. D. – E. Illustrates evoked
dopamine release in the nucleus accumbens of C57BL/6J mice following vehicle or cannabinoid administration.
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Figure 11. Stimulating electrode placements in the ventral tegmental area (VTA) of C57BL/6J and BALB/cJ mice. Grey circles
indicate the approximate anatomical location of the VTA. Black dots represent the positions of stimulating electrode lesions.
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